Company information

About Genome & Company

‘See the unseen, meet the unmet, reach the unreached’

Genome & Company is a clinical stage biotechnology company based in Republic of Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors (ICIs) to fulfill the unmet needs of cancer patients.

Our R&D program is two pronged: microbiome-based products including therapeutics, cosmeceuticals and dietary supplements, and novel-targeted immuno-oncology therapeutics.

Since our establishment in 2015, we initially started our research on microbes and probiotics which can be applied to obesity, diabetes, acne, and atopic dermatitis. Further research was invested in immuno-oncology microbiome, novel-targeted ICIs, and in 2020, our lead immuno-oncology microbiome pipeline GEN-001 has initiated clinical trials in the US.

Our technology and capabilities are evidenced by partnerships with global pharmaceutical companies such as Merck KGaA and Pfizer and other major hospitals, universities, research institutes and governments.

Our partners

We share our vision with our R&D and commercialization partners including local research centers and tertiary hospitals and global pharmaceutical companies.

Business Area

focused Research & Development




Dietary Supplements

Novel Target
Inhibitor (ICI)


Core Competency

Our pipeline has strong backbone of three pillars: novel platform technology, R&D human resources and collaborative relations with local and global networks.